ACAD — ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. (ACAD) 是一家生物科技公司，屬於醫療保健產業, 目前交易價格為 $22.02. 其SharesGrow評分為 85/100, 表明強勁的投資特徵， 7項中通過5項.

SharesGrow calculates the intrinsic value of ACAD = $24.35 (+10.6% 相對於當前價格, 該股票看起來估值合理). 分析師共識目標價為 ACAD = $35 (+57.9% 上漲空間).

估值: ACAD 本益比(P/E)為 9.7 (S&P 500平均約25) 前瞻PEG為 0.11.

財務數據: 營收為 $1.1B, +28.1%/yr 平均成長. 淨利潤為 $391M, 成長率為 +204.6%/yr. 淨利潤率為 36.5% (強勁). 毛利率為 91.7% (-6.3 pp 趨勢).

資產負債表: 總債務為 $52M 對比 $1.2B 股東權益 (D/E比率 0.04, 保守). 流動比率為 3.83 (流動性強). 資產負債率為 3.3%. 總資產: $1.6B.

分析師展望: 26 / 37 位分析師評級 ACAD 為買入 (70%) — 強烈共識.

SharesGrow 7項標準細分: Value 100/100 (Pass), Growth 100/100 (Pass), Past 50/100 (Partial), Health 100/100 (Pass), Moat 59/100 (Partial), Future 85/100 (Pass), Income 100/100 (Pass).

$34.78

▲ 57.95% 上漲空間

Average Price Target

基於 37 位華爾街分析師對 ACADIA Pharmaceuticals Inc. 提供的12個月價格目標，平均目標價為 $34.78，最高預測為 $40.00，最低預測為 $29.00。

Highest Price Target

$40.00

Average Price Target

$34.78

Lowest Price Target

$29.00

ACAD SharesGrow 評分概覽

85/100

SharesGrow Score

Strong investment profile

View full scorecard →

價值 100/100

估值 — P/E, PEG, Forward PEG

成長 100/100

財務數據 — 平均成長

過去 50/100

強勁 — 趨勢

健康 100/100

資產負債表 — D/E比率, 流動比率為

護城河 59/100

毛利率為 + market cap

未來 85/100

分析師展望 — 為買入

收入 100/100

淨利潤率為

Scores derived from financial statements, analyst ratings, and balance sheet data.

評分明細 — ACAD

✓

價值 Pass

100/100

ACAD 本益比(P/E)為 9.7 (S&P 500平均約25). Forward PEG 0.11 — Peter Lynch 被低估 (≤1.0). Trailing PEG 0.2. 分析師共識目標價為 $35, 意味著 +58.9% 相對於當前價格 $22. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + 上漲空間 (25%) + trailing PEG (20%). ≥ 60 = Pass.

ACAD: +28.1%/yr 營收為, +204.6%/yr 淨利潤為平均成長. > 5%/yr — 強勁. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

ACAD: 2 / 4 年獲利. 較弱. Score = 2 / 4 × 100. ≥ 80 = Pass.

資產負債表 ACAD: D/E比率 0.04 (保守), 流動比率為 3.83 (流動性強). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

ACAD: 毛利率為 91.7% (-6.3 pp 趨勢), $4B market cap. Moat (0-100): margin (35%) + 趨勢 (15%) + market cap (30%) + 營收為 (20%). Score 59/100. ≥ 70 = Pass.

分析師展望: 26 / 37 位分析師評級 ACAD 為買入 (70%). 分析師共識目標價為 $35 (+58.9% 上漲空間). Score: 60% buy consensus + 40% 上漲空間. ≥ 60 = Pass.

ACAD: 淨利潤率為 36.5%. 強勁 (≥30%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

市場數據

52週區間13.4-28.35

成交量1.88M

30日平均成交量1.71M

市值$3.75B

Beta（1年）0.83

Share Statistics

EPS（TTM）2.32

流通股數$169.34M

IPO Date2004-05-27

Employees653

CEOCatherine E. Owen Adams

Financial Highlights & Ratios

Revenue (TTM)$1.07B

Gross Profit$982.51M

EBITDA$138.9M

Net Income$391M

Operating Income$104.81M

Total Cash$819.69M

Total Debt$52.19M

Net Debt$-125.51M

Total Assets$1.56B

Price / Earnings (P/E)9.5

Price / Sales (P/S)3.5

Analyst Forecast

1Y Price Target$35.00

Target High$40.00

Target Low$29.00

上漲空間+58.9%

評級共識Buy

覆蓋分析師數37

買入 70% 持有 27% 賣出 3%

Price Target Summary

公司資訊

國家US

交易所NASDAQ Global Select

貨幣USD

ISINUS0042251084

股價走勢

ACAD

ACADIA Pharmaceuticals Inc. ↗ · NASDAQ Global Select

Healthcare • Biotechnology

13.40 52WK RANGE 28.35

其他人也在看

MDGL

Madrigal Pharmaceuticals, Inc.

$524.99

-0.13%

BPMC

Blueprint Medicines Corporation

$129.46

+0.14%

KRYS

Krystal Biotech, Inc.

$270.00

+0.97%

RETA

Reata Pharmaceuticals, Inc.

$172.36

+0.02%

PTCT

PTC Therapeutics, Inc.

$73.01

+3.68%

TERN

Terns Pharmaceuticals, Inc.

$52.68

+0.13%

AKRO

Akero Therapeutics, Inc.

$54.65

+0.00%

VKTX

Viking Therapeutics, Inc.

$35.52

+1.46%

ACADIA Pharmaceuticals Inc. ACAD NASDAQ

ACAD SharesGrow 評分概覽

評分明細 — ACAD

Stock Chart & Stats

股價走勢

其他人也在看

獲取低估股票提醒